

Reference number(s)
2140-A

## SPECIALTY GUIDELINE MANAGEMENT

### RIBAVIRIN PRODUCTS (COPEGUS, MODERIBA, REBETOL, RIBASPHERE, RIBASPHERE RIBAPAK, RIBATAB, ribavirin capsules and tablets)

#### POLICY

##### I. INDICATIONS

The indications below including FDA-approved indications and compendial uses are considered a covered benefit provided that all the approval criteria are met and the member has no exclusions to the prescribed therapy.

##### FDA-Approved Indications

##### Copegus

Copegus in combination with Pegasys is indicated for the treatment of patients 5 years of age and older with chronic hepatitis C (CHC) virus infection who have compensated liver disease and have not been previously treated with interferon alpha.

##### Moderiba

Moderiba in combination with peginterferon alfa-2a is indicated for the treatment of patients 5 years of age and older with CHC virus infection who have compensated liver disease and have not been previously treated with interferon alpha.

##### Rebetol

Rebetol in combination with interferon alfa-2b (pegylated and nonpegylated) is indicated for the treatment of chronic hepatitis C in patients 3 years of age and older with compensated liver disease.<sup>3</sup>

##### Ribasphere/RibaPak

Ribasphere in combination with peginterferon alfa-2a is indicated for the treatment of patients 5 years of age and older with CHC virus infection who have compensated liver disease and have not been previously treated with interferon alpha.

All other indications are considered experimental/investigational and are not a covered benefit.

##### II. EXCLUSIONS

Exclusions to other antiviral drugs being used in combination with the requested drug apply. Refer to the SGM policy for each drug in the treatment regimen for applicable exclusions.

##### III. CRITERIA FOR APPROVAL

##### **Chronic hepatitis C virus (HCV) infection**

Refer to the SGM of requested regimen for the specific criteria for approval and approval durations.

##### IV. REFERENCES

1. Copegus [package insert]. South San Francisco, CA: Genentech USA, Inc.; August 2015.
2. Moderiba [package insert]. North Chicago, IL: AbbVie Inc.; February 2015.
3. Rebetol [package insert]. Whitehouse Station, NJ: Merck & Co., Inc.; January 2016.
4. Ribasphere/Ribapak [package insert]. Warrendale, PA: Kadmon Pharmaceuticals, LLC; August 2014.

Reference number(s)
2140-A

5. AASLD/IDSA/IAS–USA. Recommendations for testing, managing, and treating hepatitis C. <http://www.hcvguidelines.org>. Last changes made on September 21, 2017. Accessed September 22, 2017.
6. Olysio [package insert]. Titusville, NJ: Janssen Products, LP; May 2017.
7. Sovaldi [package insert]. Foster City, CA: Gilead Sciences, Inc.; April 2017.
8. Viekira Pak [package insert]. North Chicago, IL: AbbVie Inc.; March 2017.
9. Technivie [package insert]. North Chicago, IL: AbbVie Inc.; March 2017.
10. Zepatier [package insert]. Whitehouse Station, NJ: Merck & Co., Inc.; February 2017.
11. Epclusa [package insert]. Foster City, CA: Gilead Sciences, Inc.; August 2017.
12. Viekira XR [package insert]. North Chicago, IL: AbbVie Inc.; March 2017.
13. Vosevi [package insert]. Foster City, CA: Gilead Sciences, Inc.; July 2017.